Is Allogene Therapeutics profitable?

Allogene Therapeutics is not currently profitable: it reported a net loss of $173.8M over the trailing twelve months, a -1170863.6% net margin.

What is Allogene Therapeutics's earnings per share?

Allogene Therapeutics's diluted EPS over the trailing twelve months is $-0.77.

Where does Allogene Therapeutics's income statement data come from?

Every line is extracted from Allogene Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Allogene Therapeutics ALLO Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Research and development	$131.96M-12.1%	$150.15M-9.8%	$166.49M-7.5%	$180.04M-5.4%	$190.24M-1.1%
General and administrative	$55.88M-1.6%	$56.78M-3.0%	$58.53M-4.2%	$61.12M-2.9%	$62.93M-3.5%
Total operating expenses	$190.22M-9.1%	$209.32M-8.0%	$227.4M-10.6%	$254.27M-5.4%	$268.89M-1.6%
Operating income	-$190.22M+9.1%	-$209.32M+8.0%	-$227.4M+10.6%	-$254.27M+5.4%	-$268.89M+1.6%
Interest expense	$1.23M+14.0%	$1.08M+27.5%	$843K+40.7%	$599K+81.0%	$331K+82.9%
Interest income	$17.35M-10.1%	$19.29M+3.4%	$18.66M-13.0%	$21.44M+5.9%	$20.24M+0.4%
Other income (expense), net	$16.46M-10.7%	$18.43M+16.4%	$15.83M-11.1%	$17.81M+4.7%	$17.01M+5.9%
Net income	-$173.76M+9.0%	-$190.89M+10.0%	-$212.02M+10.5%	-$236.91M+6.1%	-$252.32M+2.0%
Diluted earnings per share	-$0.77+11.5%	-$0.87+11.2%	-$0.98+11.7%	-$1.11+9.8%	-$1.23+7.5%
Basic earnings per share	-$0.77+11.5%	-$0.87+11.2%	-$0.98+11.7%	-$1.11+9.8%	-$1.23+7.5%
Weighted-average shares, diluted	901.9M+2.8%	876.9M+3.0%	851.1M+1.5%	838.3M+3.6%	809.4M+6.1%
Weighted-average shares, basic	901.9M+2.8%	876.9M+3.0%	851.1M+1.5%	838.3M+3.6%	809.4M+6.1%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	-$173.99M+8.7%	-$190.53M+10.1%	-$211.94M+10.3%	-$236.17M+6.0%	-$251.35M+2.1%
Interest income and other, net	$17.35M-10.1%	$19.29M+3.4%	$18.66M-13.0%	$21.44M+5.9%	$20.24M+0.4%
Unrealized gains (losses) on available-for-sale securities	-$226K-163%	$358K—	——	——	——
Other income, net (Note 6)	$335K+55.8%	$215K+111%	-$1.98M+34.5%	-$3.03M-4.4%	-$2.9M+26.0%
EBIT	-$190.22M+9.1%	-$209.32M+8.0%	-$227.4M+10.6%	-$254.27M+5.4%	-$268.89M+1.6%
EBITDA	-$178.09M+9.6%	-$196.96M+8.3%	-$214.87M+11.1%	-$241.63M+5.5%	-$255.7M+1.5%
EBITDA	-$178.09M+9.6%	-$196.96M+8.3%	-$214.87M+11.1%	-$241.63M+5.5%	-$255.7M+1.5%
EBIT	-$190.22M+9.1%	-$209.32M+8.0%	-$227.4M+10.6%	-$254.27M+5.4%	-$268.89M+1.6%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Is Allogene Therapeutics profitable?: Allogene Therapeutics is not currently profitable: it reported a net loss of $173.8M over the trailing twelve months, a -1170863.6% net margin.
What is Allogene Therapeutics's earnings per share?: Allogene Therapeutics's diluted EPS over the trailing twelve months is $-0.77.
Where does Allogene Therapeutics's income statement data come from?: Every line is extracted from Allogene Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.